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To the Editor: Residual indoor spraying with DDT or one of
the (semi) pyrethroids is a well-established method of malaria
control. It is still the main preventive means used in malaria
control programmes worldwide.1 Considerable successes have
been booked in the southern African region with programmes
depending largely on residual indoor spraying.2 However, for
this method to be effective a number of conditions have to be
met.3 Among these are factors relating to the implementation
method, timing, spraying technique, supervision, etc.
In Zimbabwe annual spraying has become a routine.
However, its effectiveness has not been firmly established.
Repeated prevalence surveys in otherwise comparable sprayed
and unsprayed areas in Mt Darwin district, Zimbabwe, showed
non-significant marginal effects in favour of spraying, namely
15% and 19% in April (peak season), and no difference in
prevalence in September (10% in both areas) (unpublished
report presented at the National Malaria Review Meeting,
Victoria Falls, 1995).
In an attempt to appraise possible effects of spraying as it is
routinely carried out (in our case with α-cypermethrine4), we
conducted a longitudinal case-controlled study in the same
area in Mt Darwin District in Mashonaland Central Province.
We followed up 400 schoolchildren (mean age 12 years)
through repeat blood slide examinations, a proven method to
estimate malaria morbidity incidence rates.5
In the group of children from sprayed villages there were 120
new episodes from a total of 23.129 days’ observation, leading
to an incidence rate (IR) of 0.623 per person season. The figure
for the unsprayed villages was 148 infections, 19.882 days and
an IR of 0.893 respectively. This difference, although slight, is
significant (p = 0.04). 
With regard to frequency of malaria, the number of episodes
per child per season was calculated and compared according to
spray status of the area. Differences were found to be
pronounced. Of the 200 children in the schools in sprayed
villages, 102 (51%) had malaria once or more as opposed to 109
(54%) in the group from the unsprayed villages. In other
words, 49% and 45.5% of children in sprayed and unsprayed
areas respectively remained malaria free (p = 0.62). 
However, children in unsprayed areas had more repeat
incidents of malaria infection; 34% versus 10% had two or
more episodes, and 9.5% versus 1% had three or more episodes
(Table I). 
These findings suggest that the spraying provided some
protection against repeat infections, but did not protect against
an initial malaria infection.
The abovementioned findings and observations made in the
field during the spraying campaign lead us to make the
following recommendations:
1. When considering such costly programmes, each of the
possible arguments for residual house spraying should be
weighed. Any national malaria vector control programme
needs sustained and authoritative input from expert
entomologists.
2. All monitoring tools available should be integrated in a
spraying programme, without which the activity should not be
embarked upon. This strict quality control routine should not
be compromised. It implies certain organisational conditions
that would lead to increased ‘verticalisation’, a situation that
carries its own disadvantages.
3. When choosing a control strategy the cost of spraying
(with ‘in-built’ quality monitoring) has to be set against the
cost of other preventive measures.
4. Recent widely tested alternative methods of vector
control6,7 are more cost effective than an insufficiently
supervised spraying campaign.8
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Residual house spraying against malaria must be done
correctly to be effective
Table I. Number of schoolchildren showing frequency of infection
by area
Severity (number Spray status
of malaria episodes) Yes No Total
None 98 91 189
One 82 41 123
Two 11 38 49
Three 8 19 27
More than three 1 11 12
Total 200 200 400
Chi-square = 20.8, p = 0.00035
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To the Editor: Many patients in South Africa develop profound
visual loss every year as a result of chloroquine toxicity. The
patients are often oblivious of the toxic effects of the drug and
have been given higher-than-recommended doses, very often
due to the ignorance of prescribing doctors. These patients
have not been sent for ocular testing. There is no means of
reversing the drug’s blinding effect.
Hydroxychloroquine (Plaquenil) is much safer than
chloroquine, with a lower risk of retinal damage (maximum
dose 400 mg/day or 6.5 mg/kg/day). It is currently available
on motivation on a named patient basis from Sanofi Synthelabo
(tel. (011) 319-8656), and should always be used instead of
chloroquine.
Chloroquine-related blindness has been almost completely
eradicated in Western countries where hydroxychloroquine is
freely available.
Maculopathy is a much less frequent occurrence and is
much less severe if hydroxychloroquine is used rather than
chloroquine.1
Chloroquine (Nivaquine, Daramal, Plasmoquine) is an
antimalarial first used during World War II. It is prescribed for
treatment of amoebiasis, rheumatoid arthritis, juvenile chronic
arthritis, systemic lupus erythematosus and discoid lupus and
as prophylaxis against malaria.
The drug is excreted very slowly from the body and
becomes concentrated in the melanin-containing cells of the
retinal pigment epithelium (RPE) and choroid.
Retinal toxicity with degeneration of the RPE and
neurosensory retina occur and are a severe sight-threatening
complication of chloroquine use.
Most cases of toxicity have developed when a higher-than-
recommended dose is used: 200 mg/day or 3.5 mg/kg/day
(using lean body weight). A total cumulative dose between 100
and 300 g is usually required to cause toxicity, i.e. 200 mg/day
for 3 years.
The earliest visual manifestation of retinal toxicity is a
paracentral scotoma. This occurs before visual acuity loss or
ophthalmoscopic fundus changes. If the drug is discontinued
the scotoma usually disappears.
By the time a characteristic bull’s eye maculopathy occurs
there is moderate visual acuity loss (6/18 - 6/12), with an area
of depigmentation around the fovea surrounded by a ring of
hypopigmentation. This enlarges slowly. This stage of
retinopathy may progress even if the drug is stopped, and
indicates irreversible damage.2
Eventually there is end-stage maculopathy with severe
visual acuity loss and marked atrophy of the RPE of the entire
retina with unmasking of the choroidal vessels as well as
secondary damage to the neurosensory retina. Retinal arteries
become attenuated, the optic disc is pale and pigment clumps
develop in the peripheral retina (pseudo-retinitis pigmentosa).
Screening is mandatory for all patients on chloroquine
therapy:3 (i) baseline examination by an ophthalmologist within
6 months of starting treatment; (ii) annual screening for the
first 5 years after starting treatment if patients are taking
higher-than-recommended doses and are at higher risk due to
age over 60 years, or associated renal/liver or retinal disease;
and (iii) 2-yearly for other low-risk users of chloroquine.
Fluorescein angiography is also helpful in early
demonstration of RPE abnormalities before vision loss occurs.
Prevention is the best form of treatment.
Strict adherence to drug dosages is imperative. The
chloroquine daily dose is thought to be more important than
the cumulative dose and should be tailored according to
gender and height (Table I).
Pressure by rheumatologists, dermatologists and
ophthalmologists to get hydroxychloroquine registered in
South Africa is critical. We encourage all prescribing doctors in
South Africa to switch their patients to hydroxychloroquine.4
This will bring us in line with other countries where
chloroquine-induced blindness has been virtually eliminated.
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Chloroquine-induced retinal toxicity
Table I. Recommended daily chloroquine dosage
Females Males
Height (cm) Tablets/week Height (cm) Tablets/week
< 146 4 < 150 5
146 - 156 5 150 - 160 6
158 - 172 6 > 162 7
> 172 7
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